TD Cowen initiated coverage of vTv Therapeutics (VTVT) with a Buy rating and $67 price target The firm thinks the company’s oral hepatoselective glucokinase activator, cadisegliatin will reduce level 2/3 hypoglycemic events and improve HbA1c levels adjunctive to insulin. TD is positive on the topline data due out in the second half of 2026. It models peak sales of $2.15B in 2037.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VTVT:
- Paradigm-Shifting Potential in Type 1 Diabetes: vTv Therapeutics’ Cadisegliatin Supports Buy Rating and Significant Upside
- vTv Therapeutics price target raised to $47 from $36 at H.C. Wainwright
- vTv submits cadisegliatin study protocol to Department of Health Abu Dhabi
- Positive Outlook for vTv Therapeutics: Buy Rating on Cadisegliatin’s Promising Phase 3 Trial and Market Potential
- vTv Therapeutics initiated with a Buy at BTIG